Aurinia Pharmaceuticals Inc

8.13-0.1400-1.69%Vol 2.01M1Y Perf -47.29%
Aug 9th, 2022 16:00 DELAYED
BID8.10 ASK8.17
Open8.08 Previous Close8.27
Pre-Market- After-Market8.09
 - -  -0.04 -0.49%
Target Price
23.81 
Analyst Rating
Strong Buy 1.25
Potential %
192.87 
Finscreener Ranking
★★★★+     57.64
Insiders Trans % 3/6/12 mo.
-/-43/-85 
Value Ranking
★★★★     55.58
Insiders Value % 3/6/12 mo.
-/-39/-99 
Growth Ranking
★★★★+     66.15
Insiders Shares Cnt. % 3/6/12 mo.
-/-35/-98 
Income Ranking
 —    -
Price Range Ratio 52W %
1.64 
Earnings Rating
Sell
Market Cap1.04B 
Earnings Date
4th Aug 2022
Alpha0.02 Standard Deviation0.26
Beta1.11 

Today's Price Range

7.958.23

52W Range

7.7033.97

5 Year PE Ratio Range

-11.30-6.50

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-2.25%
1 Month
-33.25%
3 Months
-7.55%
6 Months
-56.29%
1 Year
-47.29%
3 Years
46.63%
5 Years
38.99%
10 Years
-

TickerPriceChg.Chg.%
AUPH8.13-0.1400-1.69
AAPL164.920.05000.03
GOOG117.50-0.6400-0.54
MSFT282.301.98000.71
XOM90.591.64001.84
WFC43.400.21000.49
JNJ170.18-0.0200-0.01
FB196.640.99000.51
GE74.93-0.2500-0.33
JPM115.381.03000.90
 
ProfitabilityValueIndustryS&P 500US Markets
98.00
-253.40
-248.60
-11 756.30
-
RevenueValueIndustryS&P 500US Markets
59.70M
0.42
467.55
237.58
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.22-0.25-13.64
Q01 2022-0.26-0.27-3.85
Q04 2021-0.26-0.253.85
Q03 2021-0.31-0.39-25.81
Q02 2021-0.35-0.37-5.71
Q01 2021-0.35-0.40-14.29
Q04 2020-0.31-0.0583.87
Q03 2020-0.22-0.28-27.27
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.22-4.76Negative
9/2022 QR-0.19-11.76Negative
12/2022 FY-0.70-4.48Negative
12/2023 FY-0.11-450.00Negative
Next Report Date-
Estimated EPS Next Report-0.22
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume2.01M
Shares Outstanding128.23K
Shares Float141.32M
Trades Count15.65K
Dollar Volume16.52M
Avg. Volume3.18M
Avg. Weekly Volume3.64M
Avg. Monthly Volume3.03M
Avg. Quarterly Volume2.88M

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) stock closed at 8.27 per share at the end of the most recent trading day (a -1.19% change compared to the prior day closing price) with a volume of 3.16M shares and market capitalization of 1.04B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 294 people. Aurinia Pharmaceuticals Inc CEO is Peter S. Greenleaf.

The one-year performance of Aurinia Pharmaceuticals Inc stock is -47.29%, while year-to-date (YTD) performance is -63.84%. AUPH stock has a five-year performance of 38.99%. Its 52-week range is between 7.7 and 33.9715, which gives AUPH stock a 52-week price range ratio of 1.64%

Aurinia Pharmaceuticals Inc currently has a PE ratio of -8.20, a price-to-book (PB) ratio of 3.32, a price-to-sale (PS) ratio of 23.65, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -37.35%, a ROC of -40.34% and a ROE of -42.17%. The company’s profit margin is -%, its EBITDA margin is -248.60%, and its revenue ttm is $59.70 Million , which makes it $0.42 revenue per share.

Of the last four earnings reports from Aurinia Pharmaceuticals Inc, there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.22 for the next earnings report. Aurinia Pharmaceuticals Inc’s next earnings report date is -.

The consensus rating of Wall Street analysts for Aurinia Pharmaceuticals Inc is Strong Buy (1.25), with a target price of $23.81, which is +192.87% compared to the current price. The earnings rating for Aurinia Pharmaceuticals Inc stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aurinia Pharmaceuticals Inc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aurinia Pharmaceuticals Inc has a Sell technical analysis rating based on Technical Indicators (ADX : 13.54, ATR14 : 0.85, CCI20 : -77.09, Chaikin Money Flow : -0.05, MACD : -0.73, Money Flow Index : 40.03, ROC : -21.31, RSI : 27.64, STOCH (14,3) : 17.38, STOCH RSI : 0.24, UO : 42.52, Williams %R : -82.62), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aurinia Pharmaceuticals Inc in the last 12-months were: David R.W. Jayne (Option Excercise at a value of $36 200), George M. Milne (Buy at a value of $54 100), George Mclean Milne (Buy at a value of $54 100), Jill D. Leversage (Buy at a value of $32 064), Joseph P. Hagan (Option Excercise at a value of $203 200), Joseph P. Hagan (Sold 40 000 shares of value $903 650 ), Massimilano Colao (Sold 3 205 shares of value $38 492 ), Matthew Donley (Sold 3 052 shares of value $36 655 ), Michael R. Martin (Option Excercise at a value of $1 985 520), Michael R. Martin (Sold 504 849 shares of value $12 634 953 ), Neil Solomons (Option Excercise at a value of $1 831 700), Neil Solomons (Sold 454 846 shares of value $12 045 550 ), R. Hector Mackay-Dunn (Buy at a value of $54 985), Robert Huizinga (Option Excercise at a value of $381 715), Robert Huizinga (Sold 199 849 shares of value $5 384 945 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (75.00 %)
7 (87.50 %)
7 (87.50 %)
Moderate Buy
2 (25.00 %)
1 (12.50 %)
1 (12.50 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.25
Strong Buy
1.13
Strong Buy
1.13

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States followed by China.

CEO: Peter S. Greenleaf

Telephone: +1 250 708-4272

Address: 4464 Markham Street, Victoria V8Z 7X8, BC, CA

Number of employees: 294

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

78%22%

Bearish Bullish

67%33%

Bearish Bullish

71%29%

TipRanks News for AUPH

Wed, 27 Jul 2022 03:29 GMT Aurinia Pharmaceuticals (AUPH) Receives a Buy from SVB Securities

- TipRanks. All rights reserved.

Thu, 12 May 2022 23:44 GMT Aurinia Stock: Analyst Gets a Bit More Cautious, but Still Hits the Button

- TipRanks. All rights reserved.

Wed, 11 May 2022 07:15 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Aurinia Pharmaceuticals (AUPH) and BioNTech SE (BNTX)

- TipRanks. All rights reserved.

Fri, 06 May 2022 09:05 GMT Analysts Are Bullish on These Healthcare Stocks: Aurinia Pharmaceuticals (AUPH), Clinuvel Pharmaceuticals Limited (CLVLF)

- TipRanks. All rights reserved.

Fri, 04 Mar 2022 12:20 GMT Aurinia Pharmaceuticals (AUPH) Receives a Buy from Jefferies

- TipRanks. All rights reserved.

Mon, 28 Feb 2022 21:28 GMT Aurinia Stock Takes a Hit, but Is It Warranted Analyst Weighs In

- TipRanks. All rights reserved.

News

Stocktwits